Incidence and Risk Factors of Zidovudine-Induced Anemia in Patients With HIV Infection Receiving Zidovudine-Containing Antiretroviral Therapy.

IF 2.2 Q3 INFECTIOUS DISEASES

Journal of the International Association of Providers of AIDS Care Pub Date : 2025-01-01 DOI:10.1177/23259582251321577

Lakkana Boonyagars, Peerawit Thinpangnga, Warangkana Munsakul

{"title":"Incidence and Risk Factors of Zidovudine-Induced Anemia in Patients With HIV Infection Receiving Zidovudine-Containing Antiretroviral Therapy.","authors":"Lakkana Boonyagars, Peerawit Thinpangnga, Warangkana Munsakul","doi":"10.1177/23259582251321577","DOIUrl":null,"url":null,"abstract":"Background: Anemia is among the frequently observed conditions among people living with HIV (PLWH). Zidovudine (AZT) is the most common ART that causes anemia. This study aimed to identify the incidence and risk factors of AZT-induced anemia in PLWH receiving AZT-containing regimens.Methods: A retrospective cohort study was conducted on nonpregnant PLWH aged >18 years who received AZT-containing regimens for >6 months and had normal baseline hemoglobin levels. Data on medical history, clinical characteristics, and laboratory examination were collected. Cox proportional hazard regression analysis was performed to determine the risk factors of AZT-induced anemia.Results: A total of 401 individuals were included in the study. In total, 71 individuals presented with AZT-induced anemia. The incidence rate of anemia was 1.98 per 100 person-years of observations. Female sex, low-normal baseline hemoglobin level, low recent and low baseline CD4 cell count were independently associated with an increased risk of anemia. However, a higher body mass index was independently associated with a decreased risk of anemia.Conclusion: Routine screening, early detection, and treatment of anemia should be considered in PLWH receiving AZT-containing regimens.","PeriodicalId":17328,"journal":{"name":"Journal of the International Association of Providers of AIDS Care","volume":"24 ","pages":"23259582251321577"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863231/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Association of Providers of AIDS Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23259582251321577","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Anemia is among the frequently observed conditions among people living with HIV (PLWH). Zidovudine (AZT) is the most common ART that causes anemia. This study aimed to identify the incidence and risk factors of AZT-induced anemia in PLWH receiving AZT-containing regimens.

Methods: A retrospective cohort study was conducted on nonpregnant PLWH aged >18 years who received AZT-containing regimens for >6 months and had normal baseline hemoglobin levels. Data on medical history, clinical characteristics, and laboratory examination were collected. Cox proportional hazard regression analysis was performed to determine the risk factors of AZT-induced anemia.

Results: A total of 401 individuals were included in the study. In total, 71 individuals presented with AZT-induced anemia. The incidence rate of anemia was 1.98 per 100 person-years of observations. Female sex, low-normal baseline hemoglobin level, low recent and low baseline CD4 cell count were independently associated with an increased risk of anemia. However, a higher body mass index was independently associated with a decreased risk of anemia.

Conclusion: Routine screening, early detection, and treatment of anemia should be considered in PLWH receiving AZT-containing regimens.

查看原文本刊更多论文

接受含齐多夫定抗逆转录病毒治疗的HIV感染者齐多夫定致贫血的发生率及危险因素

背景：贫血是HIV感染者（PLWH）中常见的疾病之一。齐多夫定（AZT）是最常见的导致贫血的抗逆转录病毒治疗药物。本研究旨在确定接受含azt方案的PLWH患者azt诱导贫血的发生率和危险因素。方法：采用回顾性队列研究方法，研究对象为年龄为100 ~ 18岁、接受azt治疗6个月、基线血红蛋白水平正常的非妊娠PLWH患者。收集病史、临床特征和实验室检查资料。采用Cox比例风险回归分析确定azt致贫血的危险因素。结果：共有401人被纳入研究。总共有71人出现azt引起的贫血。贫血的发生率为1.98 / 100人-年观察。女性、低正常基线血红蛋白水平、低近期和低基线CD4细胞计数与贫血风险增加独立相关。然而，较高的身体质量指数与贫血风险降低独立相关。结论：接受含azt方案的PLWH应考虑常规筛查、早期发现和治疗贫血。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊